Provided by Tiger Trade Technology Pte. Ltd.

Kronos Bio, Inc.

0.8800
0.0000
Volume:- -
Turnover:47.16K
Market Cap:53.73M
PE:-0.82
High:0.8800
Open:0.8800
Low:0.8800
Close:0.8800
52wk High:1.60
52wk Low:0.6500
Shares:61.05M
Float Shares:43.94M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0678
EPS(LYR):-1.4330
ROE:-59.49%
ROA:-21.73%
PB:0.67
PE(LYR):-0.61

Loading ...

Company Profile

Company Name:
Kronos Bio, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial; and Lanraplenib, a next-generation SYK inhibitor to treat the patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. The company was incorporated in 2017 and is headquartered in San Mateo, California.